The Prevalence of Serum Anti Nuclear Antibodies in Children Treated With Anti-Epileptics
Abstract
To evaluate the prevalence of positive serum antinuclear antibody (ANA) in children with epilepsy using three major antiepileptic drugs (phenytoin, carbamazepine and ethosuximide), 60 children under 18 years with epilepsy who were referred to pediatric neurology clinic or had admitted to neurology ward in Children Hospital in Tehran, Iran, were entered our study. They had been treated with one of the three antiepileptic drugs (carbamazepin, phenytoin, ethosuximide) with suitable dose for at least one month. The patients were divided into two groups according to the classification of the International League Against Epilepsy (ILAE): drug-resistant and drug-responsive. We studied the epidemiological and clinical characteristics and also serum ANA of the patients in both groups. In this research, we studied ANA in 60 epileptic children. 30 patients were diagnosed with drug resistant epilepsy and the other 30 were drug responsive. None of them showed the clinical manifestations of lupus erythematosus. As a whole, 7 patients (11.7%) were ANA-positive, 6.7% of drug resistant and 16.7% of drug responsive group showed this finding. There was no relationship between drug resistancy and ANA according to statistical studies (P=0.21). Although in our study, epidemiological and clinical data of the patients was reported in two separate groups of resistant or responsive to antiepileptic drugs, and no meaningful statistical difference was found between these two groups. Overally in our study, the prevalence of positive ANA in patients receiving antiepileptic drugs was less in comparison with previous studies and was more common in males. Finally, we suggest a more comprehensive and extensive study with more cases and further follow-up period in order to find the cause of immunological reactions to antiepileptic drugs in children with epilepsy.
2. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 2018;30:490-7.
3. Swaiman KF AS, Ferriero DM, Schor NF. Swaiman’s Pediatric Neurology. Philadelphia: Elsevier Saunders; 2012.
4. Kliegman RM SB, St Geme III JW, Schor NF, Behrman RE. Nelson Textbook of Pediatrics. Philadelphia: Elsevier; 2016.
5. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538-46.
6. Papadopoulou E, Saroglou M, Ismailos G, Fletsios D, Tsavlis D, Tryfon S. Pearls for the diagnosis and possible pathophysiological mechanisms of valproic acid-induced lupus erythematosus: A literature review. Lupus 2022;31:650-8.
7. Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, et al. Drug-induced lupus: Traditional and new concepts. Autoimmun Rev 2018;17:912-8.
8. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77.
9. Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev 2020;72:606-38.
10. Fricke-Galindo I, Jung-Cook H, A LL, López-López M. Pharmacogenetics of adverse reactions to antiepileptic drugs. Neurologia (Engl Ed) 2018;33:165-76.
11. Moosa ANV. Antiepileptic Drug Treatment of Epilepsy in Children. Continuum (Minneap Minn) 2019;25:381-407.
12. Singsen BH, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics 1976;57:529-34.
13. Rubin RL. Drug-induced lupus. Toxicology. 2005;209:135-47.
14. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007;1108:166-82.
15. Asadi-Pooya AA, Asadi-Pooya K. Antinuclear antibodies in children with epilepsy treated by carbamazepine. Epilepsy Res 2008;80:229-30.
16. Beernink DH, Miller JJ. Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J Pediatr 1973;82:113-7.
17. Peltola JT, Haapala A, Isojärvi JI, Auvinen A, Palmio J, Latvala K, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000;109:712-7.
18. Ranua J, Luoma K, Peltola J, Haapala AM, Raitanen J, Auvinen A, et al. Anticardiolipin and antinuclear antibodies in epilepsy--a population-based cross-sectional study. Epilepsy Res 2004;58:13-8.
19. Pashnina IA, Krivolapova IM, Fedotkina TV, Ryabkova VA, Chereshneva MV, Churilov LP, et al. Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease. Antibodies (Basel) 2021;10:9.
20. Crespel A, Velizarova R, Agullo M, Gélisse P. Ethosuximide-induced de novo systemic lupus erythematosus with anti-double-strand DNA antibodies: a case report with definite evidence. Epilepsia 2009;50:2003.
Files | ||
Issue | Vol 61 No 7 (2023) | |
Section | Original Article(s) | |
DOI | https://doi.org/10.18502/acta.v61i7.14497 | |
Keywords | ||
Antinuclear antibody Antiepileptic drugs Children |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |